<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168281">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049099</url>
  </required_header>
  <id_info>
    <org_study_id>Sobi.HAEM89-001</org_study_id>
    <nct_id>NCT02049099</nct_id>
  </id_info>
  <brief_title>A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care</brief_title>
  <official_title>A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <authority>Spain: Departament de Salut de la Generalitat de Catalunya</authority>
    <authority>Spain: Consejería de Sanidad de la Comunidad de Madrid</authority>
    <authority>Germany : Kassenärztliche Bundesvereinigung (KBV)</authority>
    <authority>Germany : GKV-Spitzenverband</authority>
    <authority>Germany : PKV - Verband der Privaten Krankenversicherung</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the current treatment practice during 12 months for previously treated patients
      diagnosed with haemophilia A or haemophilia B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population consists of patients with a diagnosis of ICD10: haemophilia A D66.9 or
      haemophilia B D67.9.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Total dose (IU) issued of Factor VIII during a 12 month period</measure>
    <time_frame>- 12 month to Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Total dose (IU) issued of Factor IX during a 12 month period</measure>
    <time_frame>- 12 month to Day 0</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia B</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients with a diagnosis of ICD10: haemophilia A D66.9
        or haemophilia B D67.9.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients with severe or moderate haemophilia A or haemophilia B.

          -  Treatment with Factor VIII/Factor IX products initiated at least 24 months    before
             inclusion in the study.

          -  Informed consent is obtained from the patient or patient's legal representative (as
             applicable according to legal regulation).

        Exclusion Criteria:

          -  Confirmed positive inhibitor test detected in the past 24 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Lethagen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Swedish Orphan Biovitrum AB (publ)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla Pettersson, B.Sc.</last_name>
    <phone>+4686972000</phone>
    <email>camilla.pettersson@sobi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lena Sörskog, M.Sc.</last_name>
    <phone>+4686972000</phone>
    <email>lena.sorskog@sobi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unidad de Hemofilia, Hospital Vall d´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>119-129</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Servicio de Hematología, Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
